Investment
Features
FeesSafety
Academy
More
Pluang+

Chord Energy to release Q3 2026 results on Nov 4, with webcast and call on Nov 5

Company Fundamentals
19 Oct 2026
PRNewsWire
View Source
Neutral
Chord Energy to release Q3 2026 results on Nov 4, with webcast and call on Nov 5

Chord Energy Corp. will announce its third quarter 2026 financial and operating results on November 4, 2026, after market close. The company will host a live webcast and conference call on November 5 at 10:00 a.m. Central time for investors and analysts to discuss the results. Additionally, Chord Energy plans to participate in several upcoming energy conferences through December 2026. This event is important for investors to assess the company's performance and outlook in the energy sector.

Chord Energy's upcoming third quarter 2026 earnings release is a key event for market watchers. For readers following the energy sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Among 79 priced Energy-sector US stocks, 35 rose and 43 fell today. Notable movers include Suncor Energy Inc. (SU) at USD 78.56 with a 1-day change of +3.86% and a typical hold time on Pluang of 57 days, Canadian Natural Resources Ltd. (CNQ) at USD 53.82 with +3.60% change and 71 days hold time, and ConocoPhillips (COP) at USD 146.64 with +3.46% change and 80 days hold time. Pluang order activity varies, with SU seeing 61% sell orders, CNQ 97% sell, and COP 48% sell.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App